[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100604555":3},{"organization":4,"armGroups":7,"interventions":14,"overallOfficials":20,"centralContacts":21,"locations":27,"responsibleParty":65,"collaborators":20,"id":67,"slug":20,"hasResults":68,"nctId":69,"briefTitle":70,"officialTitle":71,"acronym":72,"eligibilityCriteria":73,"healthyVolunteers":68,"sex":74,"minAge":75,"maxAge":20,"enrollmentInfo":76,"targetDuration":20,"studyType":79,"phases":80,"briefSummary":83,"conditions":84,"keywords":20,"overallStatus":30,"whyStopped":20,"lastUpdateSubmitDate":91,"lastUpdatePostDateStruct":92,"startDateStruct":95,"completionDateStruct":97,"leadSponsor":99,"locationsCount":101},{"fullName":5,"class":6},"OneCarbon","INDUSTRY",[8],{"label":9,"type":10,"description":11,"interventionNames":12},"Single arm dose","EXPERIMENTAL","Phase 1a (escalation) Single arm dose escalation of TH9619 as monotherapy. Phase 1b (expansion) Single arm dose expansion of TH9619 as monotherapy in selected tumor types.",[13],"Drug: TH9619",[15],{"type":16,"name":17,"description":18,"armGroupLabels":19,"otherNames":20},"DRUG","TH9619","Phase 1a - DOSE ESCALATION\n\nDescription:\n\nSingle arm dose escalation of TH9619 as monotherapy.\n\nPhase 1b - DOSE EXPANSION\n\nDescription:\n\nSingle arm dose expansion of TH9619 as monotherapy in selected tumor types. The objectives and endpoints for the expansion cohort(s) will be defined in a protocol amendment, once data from Phase 1a are available.",[9],null,[22],{"name":23,"role":24,"phone":25,"phoneExt":20,"email":26},"Victoria Moody","CONTACT","+46708555182","victoria.moody@one-carbon.com",[28,39,48,56],{"facility":29,"status":30,"city":31,"state":20,"zip":20,"country":32,"cosmosGeoPoint":33,"geoPoint":38,"contacts":20},"Institut Gustave Roussy","RECRUITING","Villejuif","France",{"type":34,"coordinates":35},"Point",[36,37],2.35992,48.7939,{"lat":37,"lon":36},{"facility":40,"status":30,"city":41,"state":20,"zip":20,"country":42,"cosmosGeoPoint":43,"geoPoint":47,"contacts":20},"Vall D Hebron Institute Of Oncology","Barcelona","Spain",{"type":34,"coordinates":44},[45,46],2.15899,41.38879,{"lat":46,"lon":45},{"facility":49,"status":30,"city":50,"state":20,"zip":20,"country":42,"cosmosGeoPoint":51,"geoPoint":55,"contacts":20},"Hospital Universitario Fundacion Jimenez Diaz","Madrid",{"type":34,"coordinates":52},[53,54],-3.70256,40.4165,{"lat":54,"lon":53},{"facility":57,"status":30,"city":58,"state":20,"zip":20,"country":59,"cosmosGeoPoint":60,"geoPoint":64,"contacts":20},"Newcastle University","Newcastle upon Tyne","United Kingdom",{"type":34,"coordinates":61},[62,63],-1.61396,54.97328,{"lat":63,"lon":62},{"type":66,"investigatorFullName":20,"investigatorTitle":20,"investigatorAffiliation":20,"oldNameTitle":20,"oldOrganization":20},"SPONSOR","100604555",false,"NCT07151040","Phase 1\u002F2 Study to Evaluate TH9619 in the Treatment of Advanced Solid Tumors","A First-in-human, Phase 1\u002F2, Multicenter, Open-label, Dose Escalation, Confirmation and Expansion Study to Evaluate the Safety, Pharmacokinetics and Antitumor Activity of TH9619 in Subjects With Advanced Solid Tumors","ODIN","Inclusion Criteria:\n\n* Must have given written informed consent\n* Histopathologically confirmed advanced cancer (colorectal cancer, head and neck squamous cell cancer, non-small cell lung cancer and gastric cancer (including gastroesophageal junction cancer))\n* Prior treatment with at least one line of cytotoxic systemic therapy for metastatic\u002Funresectable cancer\n* Adult patients (≥18 years of age)\n* Must be willing to comply with study procedures\n\nExclusion Criteria:\n\n• History or presence of any clinically significant disorders as judged by the Investigator.","ALL","18 Years",{"count":77,"type":78},43,"ESTIMATED","INTERVENTIONAL",[81,82],"PHASE1","PHASE2","This is a first in human, multi-center, open-label, dosage escalation study to determine the recommended dose range of TH9619 in subjects with advanced cancer.",[85,86,87,88,89,90],"Solid Tumor","Colorectal Cancer (CRC)","Squamous Cell Carcinoma of Head and Neck","Non-Small Cell Lung Cancer (NSCLC)","Gastrooesophageal Junction Cancer","Gastric Cancer","2026-01-27",{"date":93,"type":94},"2026-01-28","ACTUAL",{"date":96,"type":94},"2025-08-22",{"date":98,"type":78},"2026-12",{"name":100,"class":6},"One-carbon Therapeutics AB",4]